1. Hong Kong Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Meilleure Health International Industry Group Limited

Meilleure Health International Industry Group Limited

HHKEX:2327
0.18
HKD
0.00
(0.00%)
1.08BMarket Cap
Meilleure Health International Industry Group Limited
HKEX:2327
(Hong Kong Exchange)

Recent

price

0.18

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
HKD
0.1
0.12
0.02
0.02
0.01
0.03
0.02
0.02
0.06
0.06
0.06
0.06
0.03
0.03
0.01
0.01
- -
Revenue per Share
0.15
0.04
0.02
0.05
- -
- -
0.01
0.02
0.02
- -
0.02
0.01
- -
0.01
0.01
0.01
- -
Basic EPS, GAAP
0.15
0.06
0.03
0.04
- -
-0.02
-0.1
-0.02
- -
0.01
0.02
-0.02
0.01
-0.03
0.05
-0.01
- -
Free Cash Flow per Basic Share
0.02
0.06
0.02
0.1
- -
- -
- -
0.01
- -
- -
- -
- -
- -
0.02
- -
0.01
- -
Dividend per Share
0.36
0.36
0.36
0.05
0.06
0.13
0.19
0.19
0.21
0.29
0.33
0.34
0.32
0.31
0.29
0.31
0.31
Book Value per Share
0.35
0.34
0.36
0.05
0.06
0.13
0.16
0.17
0.19
0.29
0.32
0.34
0.32
0.3
0.29
0.31
0.31
Tangible Book Value per Share
1,701
1,701
1,715
1,732
1,733
2,011
2,715
3,330
3,742
4,173
4,272
4,257
4,109
4,093
4,093
4,064
4,064
Basic Weighted Avg Shares
175
204
36
35
9
57
67
69
231
235
265
253
120
129
51
37
- -
Sales/Revenue/Turnover
12.68
7.25
-26.48
-39.32
-22.95
25.99
-0.95
22.91
24.98
13.99
23.84
23.21
28.09
30.44
-3.53
-23.39
- -
Operating Margin (%)
17
1
1
- -
1
3
2
1
1
6
8
4
4
3
2
1
- -
Depreciation Expense
256
71
42
89
2
8
34
80
81
-20
83
60
18
41
32
38
- -
Net Income, GAAP
8.73
6.16
11.75
26.58
27.94
59.6
29.41
23
23.51
- -
17.88
29.46
29.96
27.35
29.42
- -
- -
Effective Tax Rate (%)
145.84
34.65
117.13
254.34
21.22
13.57
51.58
116.54
34.93
-8.59
31.47
23.84
14.86
31.58
64.09
104.01
- -
Profit Margin (%)
186
121
118
53
54
244
213
191
278
647
851
765
785
695
530
654
654
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
143
122
111
169
137
219
109
109
LT Debt
607
605
616
95
97
315
562
686
822
1,266
1,403
1,431
1,327
1,254
1,201
1,248
1,248
Total Equity
2.99
4.37
1.74
14.18
1.14
2.42
0.4
1.32
3.82
- -
3.99
3.04
1.96
0.86
-0.8
- -
- -
Return on Invested Capital (%)
41.29
9.21
5.52
18.24
1.14
3.02
7.77
12.43
9.62
- -
5.9
4.18
1.63
3.29
2.63
- -
- -
Return on Capital (%)
51.45
11.65
6.84
25.09
2.06
3.75
7.87
12.9
10.74
-1.94
6.27
4.26
1.29
3.17
2.65
3.1
- -
Return on Common Equity (%)

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
84
94
272
LT Borrowings
219
251
109
LT Finance Leases
1
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4,093
4,063
4,063
Market Capitalization
1,187
1,199
1,077

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
688
750
1,016
Cash, Cash Equivalents & STI
30
10
13
Accounts Receivable, Net
27
19
16
Inventories
257
311
374
Total Current Liabilities
158
184
362
Payables & Accruals
- -
- -
- -
ST Debt
84
94
272
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.41%
-2.22%
3.9%
Free Cash Flow
-63.35%
-232.64%
-127.23%
Net Income, GAAP
-13.32%
5.49%
16.94%
Sales/Revenue/Turnover
13.22%
-27.62%
-27.94%
Total Cash Common Dividend
- -
- -
37.5%

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
129
2024
- -
- -
51
2025
- -
- -
37

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.01
2024
- -
- -
0.01
2025
- -
- -
0.01

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.02
2024
- -
- -
- -
2025
- -
- -
0.01
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Meilleure Health International Industry Group Limited Meilleure Health International Industry Group Limited (2327.HK) is a Bermuda-incorporated investment holding company listed on the Main Board of The Stock Exchange of Hong Kong Limited, primarily engaged in healthcare-related businesses, industrial hemp production, trading activities, property development and investment, and equity investments across Hong Kong, the People's Republic of China, Europe, Switzerland, Japan, Australia, France, and other international markets. Founded in 2002 and headquartered at Unit 2906, Tower 1, Lippo Centre, 89 Queensway, Admiralty, Hong Kong, the company operates through key segments including healthcare services such as health management, anti-aging treatments, aesthetic medical services, and stem cell therapies via subsidiaries like La Clinique de Paris, La Clinique Eden in Switzerland, and Wingor Biotech; industrial hemp and cannabidiol (CBD) downstream products through Yunnan Hansu, recognized as China's largest CBD extraction firm, and Meilleure Hemp Health Europe; trading of construction materials, renewable energy products, and provision of procurement and sales agency services for healthcare-related items; property-related activities encompassing residential property development and sales, property investment, leasing, and operations like Le Baron Tavernier Hotel & SPA; as well as healthy lifestyle offerings including high-end CBD cosmetics, sports supplements, anti-hangover pills, COVID-19 supplements, in vitro diagnostics such as PCR and antigen tests, pharmaceuticals for prevention and treatment, and medical equipment. The company, formerly known as U-Home Group Holdings Limited, underwent a significant rebranding in March 2017 to emphasize its strategic pivot toward health and wellness sectors; in recent developments, it has expanded its Swiss operations since 2020 for cosmetics and supplements production, continued as a forefront provider of COVID-19 medical equipment including PCR tests and antigen tests since 2019, and experienced notable shareholder activity in 2024-2025 with Zhongjia U-Home Investment Limited increasing its stake multiple times to reach approximately 33.92% through acquisitions of ordinary shares valued at millions of HKD, alongside revenue growth from property-related businesses and interest income from short-term loans to customers and related parties.